Related Experiment Video

Updated: Aug 14, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

[Dose finding for clinical trials of antiarrhythmic substances (author's transl)]

K J Hahn

    Arzneimittel-Forschung
    |February 1, 1977
    PubMed

    Insights

    Clinical evaluation and dose finding for antiarrhythmic drugs present challenges due to variable arrhythmia symptoms and patient factors. Careful patient selection and monitoring of plasma levels are crucial for effective antiarrhythmic therapy.

    Area of Science:

    • Pharmacology
    • Clinical Medicine
    • Cardiology

    Context:

    • Clinical evaluation and dose-finding studies for antiarrhythmic substances are complex.
    • Arrhythmia presents with diverse pathogenesis, clinical significance, and inconsistent symptoms.

    Purpose:

    • To discuss specific challenges in the clinical evaluation and dose finding of antiarrhythmic agents.
    • To highlight the need for specialized cardiologic expertise in interpreting antiarrhythmic studies.

    Summary:

    • Difficulties arise from the heterogeneity of arrhythmia presentation and pathophysiology.
    • Patient selection and monitoring of plasma drug concentrations are vital.
    • Methods for determining therapeutic dosage and documenting side effects are essential.

    Impact:

    • Improved methodologies for antiarrhythmic drug development and clinical trials.
    • Enhanced understanding of factors influencing antiarrhythmic drug efficacy and safety.
    • Guidance for clinicians in managing patients with cardiac arrhythmias.

    More Related Videos

    Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology10:41

    Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

    Published on: September 13, 2022

    Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes09:17

    Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

    Published on: August 9, 2022

    Related Concept Videos

    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Dose Size and Dosing Frequency: Determination Methods01:21

    Dose Size and Dosing Frequency: Determination Methods

    Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...